Development of TV003/TV005, a single dose, highly immunogenic live attenuated dengue vaccine; what makes this vaccine different from the Sanofi-Pasteur CYD™ vaccine?

被引：119

作者：

Whitehead, Stephen S. ^{[1
]}

机构：

[1] NIAID, Infect Dis Lab, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA

来源：

EXPERT REVIEW OF VACCINES | 2016年 / 15卷 / 04期

关键词：

vaccine infectivity; vaccine attenuation strategies; vaccine immunogenicity; vaccine efficacy; Dengue; live attenuated dengue vaccine; FLAVIVIRUS-NAIVE ADULTS; HEMORRHAGIC-FEVER; VIRUS TYPE-4; TETRAVALENT; HEALTHY; INFECTIONS; RESPONSES; TRIAL; SAFE; ENHANCEMENT;

D O I：

10.1586/14760584.2016.1115727

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Dengue is caused by four serotype-distinct dengue viruses (DENVs), and developing a multivalent vaccine against dengue has not been straightforward since partial immunity to DENV may predispose to more severe disease upon subsequent DENV infection. The vaccine that is furthest along in development is CYD (TM), a live attenuated tetravalent vaccine (LATV) produced by Sanofi Pasteur. Although the multi-dose vaccine demonstrated protection against severe dengue, its overall efficacy was limited by DENV serotype, serostatus at vaccination, region and age. The National Institute of Allergy and Infectious Diseases has developed the LATV dengue vaccines TV003/TV005. A single dose of either TV003 or TV005 induced seroconversion to four DENV serotypes in 74-92% (TV003) and 90% (TV005) of flavivirus seronegative adults and elicited near-sterilizing immunity to a second dose of vaccine administered 6-12 months later. The important differences in the structure, infectivity and immune responses to TV003/TV005 are compared with CYD (TM).

引用

页码：509 / 517

页数：9

共 27 条

[1] A PROSPECTIVE-STUDY OF DENGUE INFECTIONS IN BANGKOK [J].

BURKE, DS ;

NISALAK, A ;

JOHNSON, DE ;

SCOTT, RM .

AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 1988, 38 (01) :172-180

[2] Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial [J].

Capeding, Maria Rosario ;

Ngoc Huu Tran ;

Hadinegoro, Sri Rezeki S. ;

Ismail, Hussain Imam H. J. Muhammad ;

Chotpitayasunondh, Tawee ;

Chua, Mary Noreen ;

Chan Quang Luong ;

Rusmil, Kusnandi ;

Wirawan, Dewa Nyoman ;

Nallusamy, Revathy ;

Pitisuttithum, Punnee ;

Thisyakorn, Usa ;

Yoon, In-Kyu ;

van der Vliet, Diane ;

Langevin, Edith ;

Laot, Thelma ;

Hutagalung, Yanee ;

Frago, Carina ;

Boaz, Mark ;

Wartel, T. Anh ;

Tornieporth, Nadia G. ;

Saville, Melanie ;

Bouckenooghe, Alain .

LANCET, 2014, 384 (9951) :1358-1365

[3] Safety and immunogenicity of three tetravalent dengue vaccine formulations in healthy adults in the USA [J].

Dayan, Gustavo H. ;

Thakur, Manoj ;

Boaz, Mark ;

Johnson, Carol .

VACCINE, 2013, 31 (44) :5047-5054

[4] rDEN2/4Δ30(ME), a live attenuated chimeric dengue serotype 2 vaccine, is safe and highly immunogenic in healthy dengue-naive adults [J].

Durbin, Anna P. ;

McArthur, Julie H. ;

Marron, Jennifer A. ;

Blaney, Joseph E. ;

Thumar, Bhavin ;

Wanionek, Kimberli ;

Murphy, Brian R. ;

Whitehead, Stephen S. .

HUMAN VACCINES, 2006, 2 (06) :255-260

[5] A Single Dose of Any of Four Different Live Attenuated Tetravalent Dengue Vaccines Is Safe and Immunogenic in Flavivirus-naive Adults: A Randomized, Double-blind Clinical Trial [J].

Durbin, Anna P. ;

Kirkpatrick, Beth D. ;

Pierce, Kristen K. ;

Elwood, Daniel ;

Larsson, Catherine J. ;

Lindow, Janet C. ;

Tibery, Cecilia ;

Sabundayo, Beulah P. ;

Shaffer, Donna ;

Talaat, Kawsar R. ;

Hynes, Noreen A. ;

Wanionek, Kimberli ;

Carmolli, Marya P. ;

Luke, Catherine J. ;

Murphy, Brian R. ;

Subbarao, Kanta ;

Whitehead, Stephen S. .

JOURNAL OF INFECTIOUS DISEASES, 2013, 207 (06) :957-965

[6] Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine [J].

Durbin, Anna P. ;

Kirkpatrick, Beth D. ;

Pierce, Kristen K. ;

Schmidt, Alexander C. ;

Whitehead, Stephen S. .

VACCINE, 2011, 29 (42) :7242-7250

[7] rDEN4Δ30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers [J].

Durbin, AP ;

Whitehead, SS ;

McArthur, J ;

Perreault, JR ;

Blaney, JE ;

Thumar, B ;

Murphy, BR ;

Karron, RA .

JOURNAL OF INFECTIOUS DISEASES, 2005, 191 (05) :710-718

[8]

Durbin AP, 2010, AM SOC TROP MED HYG

[9] Analysis of repeat hospital admissions for dengue to estimate the frequency of third or fourth dengue infections resulting in admissions and dengue hemorrhagic fever, and serotype sequences [J].

Gibbons, Robert V. ;

Kalanarooj, Siripen ;

Jarman, Richard G. ;

Nisalak, Ananda ;

Vaughn, David W. ;

Endy, Timothy P. ;

Mammen, Mammen P., Jr. ;

Srikiatkhachorn, Anon .

AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2007, 77 (05) :910-913

[10] Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease [J].

Hadinegoro, S. R. ;

Arredondo-Garcia, J. L. ;

Capeding, M. R. ;

Deseda, C. ;

Chotpitayasunondh, T. ;

Dietze, R. ;

Ismail, H. I. Hj Muhammad ;

Reynales, H. ;

Limkittikul, K. ;

Rivera-Medina, D. M. ;

Tran, H. N. ;

Bouckenooghe, A. ;

Chansinghakul, D. ;

Cortes, M. ;

Fanouillere, K. ;

Forrat, R. ;

Frago, C. ;

Gailhardou, S. ;

Jackson, N. ;

Noriega, F. ;

Plennevaux, E. ;

Wartel, T. A. ;

Zambrano, B. ;

Saville, M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (13) :1195-1206

← 1 2 3 →